First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma
Human epidermal growth factor receptor 2 (HER2) is a transmembrane glycoprotein with intracellular tyrosine kinase activity, often considered a poor prognostic marker. Targeted therapies, such as small molecule tyrosine kinase inhibitors (TKIs), have shown limited effectiveness in treating HER2-mutant advanced nonsmall cell lung cancer (NSCLC). According to the 2023 National Comprehensive Cancer Network (NCCN) guidelines for NSCLC, the antibody-drug conjugate trastuzumab emtansine is recommended for HER2-mutant lung cancer treatment. However, this drug is not approved in certain regions, highlighting the need for alternative treatment options for HER2-mutant NSCLC patients. In our study of a patient with HER2 exon 20 insertion lung adenocarcinoma, who had previously failed multiple epidermal growth factor receptor (EGFR)-TKI treatments, we found that sunvozertinib helped stabilize the patient’s condition, achieving a progression-free survival of 87 days. This novel finding may offer a new treatment option for HER2 exon 20 insertion patients who have failed DZD9008 TKI therapy.